Merck (NYSE:MRK) reported progress on its investigational oral PCSK9 inhibitor, enlicitide decanoate, including a ...
Regulatory Engagement -- Codexis is preparing a briefing for its next FDA interaction as part of the Emerging Technologies ...
They can weather many storms.
An $80,000 annual income sits at a meaningful threshold. It roughly matches the combined Social Security benefit. It is ...
The Gabelli Healthcare & WellnessRx Trust offers defensive exposure amid 2026's tech-driven market euphoria. Read more on GRX ...
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities ...
Futures are trading higher on Wednesday as news of an impending end to the Iran war is sending oil prices dramatically lower.
Merck (NYSE:MRK) delivered its fourth consecutive earnings beat, but shares slipped on the earnings report. With acquisition charges clouding the quarter, here is where the stock heads next. The 24/7 ...
Terns is now a wholly-owned subsidiary of Merck and its stock will no longer be listed or traded on the Nasdaq Global Select ...
Stroke drug developer Argenica Therapeutics plans a second trial to test its novel candidate, in a sector that has few ...
It's time to start thinking at least a little bit defensively by exchanging long-term potential gains for certain near-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results